Ongoing Clinical Trials for Ulcerative Colitis
Currently, 89 clinical trials are evaluating new treatments for ulcerative colitis, a chronic inflammatory bowel disease affecting the large intestine and rectum. These studies are testing various medications including biologics, small molecule drugs, and novel therapies across multiple countries in Europe and beyond, offering patients opportunities to access experimental treatments while contributing to medical research.
Clinical trial locations
- Austria
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab
- Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis
- Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
- Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study on Etrasimod for Adolescents with Moderate to Severe Ulcerative Colitis
- Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Effects of Mirikizumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- See more trials
- Belgium
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis
- Exploring Precision Dosing of Infliximab for Patients with Steroid-Resistant Severe Ulcerative Colitis
- Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
- Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
- Study of Oral NX-13 for Patients with Moderate to Severe Ulcerative Colitis
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- See more trials
- Bulgaria
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- Study on Etrasimod Arginine for Patients with Ulcerative Colitis, Alopecia Areata, Atopic Dermatitis, and Eosinophilic Esophagitis
- Study on Long-Term Effects of Mirikizumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Study on Mesalazine for Patients with Mild to Moderate Ulcerative Colitis
- Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis
- Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis
- Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis
- Study on the Effects of MORF-057 for Adults with Moderate to Severe Ulcerative Colitis
- See more trials
- Croatia
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
- Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Vedolizumab for Children with Moderate to Severe Ulcerative Colitis
- Czechia
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis
- Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
- Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Effects of Mirikizumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Study on Mesalazine for Patients with Mild to Moderate Ulcerative Colitis
- See more trials
- Denmark
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study of Orismilast for Treating Moderate to Severe Ulcerative Colitis in Adults
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Vedolizumab and Ustekinumab for Patients with Crohn’s Disease and Ulcerative Colitis
- Estonia
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis
- Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on the Effects of MORF-057 for Adults with Moderate to Severe Ulcerative Colitis
- Finland
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study on Fecal Microbiota Transplantation with Infliximab and Vedolizumab for Patients with Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- France
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab
- Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
- Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- See more trials
- Germany
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis
- Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis
- Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
- Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
- Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis
- Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis
- See more trials
- Greece
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
- Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate-to-Severe Ulcerative Colitis
- Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis
- Hungary
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Effects of Mirikizumab for Patients with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- See more trials
- Ireland
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
- Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis
- Italy
- Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies
- Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab
- Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis
- Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
- Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
- Study on the Effectiveness and Safety of Golimumab for Children with Moderate to Severe Ulcerative Colitis
- Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
- Study of Oral NX-13 for Patients with Moderate to Severe Ulcerative Colitis
- Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis
- Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
- See more trials
- Latvia
